Immunoassay Platform
Biomolecular interaction analysis lies at the heart of modern biopharmaceutical R&D and quality control, serving as the foundation for target validation, drug efficacy assessment, and safety compliance. As a core analytical approach for studying such interactions, immunoassay technology operates on the principle of highly specific, reversible antibody-antigen recognition, a hallmark of biological specificity that enables selective detection of target molecules within complex biological matrices. This technology excels at characterizing biomolecular interactions, making it essential in biopharmaceutical R&D and quality control. It enables the evaluation of drug-target binding affinity, the verification of therapeutic protein identity and integrity, the quantification of trace impurities, and the confirmation of functional potency. By directly mirroring physiologically relevant molecular interactions, immunoassays provide biologically meaningful data that underpin safety, efficacy, and regulatory compliance across the entire drug lifecycle.
Immunoassay Platform
PharmaAnalytica's Immunoassay Platform is a fully integrated analytical ecosystem dedicated to biomolecular interaction and biopharmaceutical analysis, unifying advanced immunoassay technologies, high-performance instruments, and standardized workflows. Designed to address the full lifecycle demands of biologic drugs—from early target discovery to commercial release—the platform delivers precise, reproducible, and traceable data for antibody drugs, recombinant proteins, vaccines, and cell therapy products. It bridges the gap between basic research and industrial application, empowering biopharmaceutical developers to accelerate innovation, ensure product consistency, and meet stringent global regulatory standards.
WB‑1200Auto Fully Automated Western Blot Processing System
WB-1200Auto delivers fully automated workflows including blocking, antibody incubation, and washing, with the capacity to process up to 12 membranes simultaneously under precise temperature control, compatible with 1–4 gel electrophoresis setups and seamlessly integrable with imaging systems to minimize manual error and improve result reproducibility; it is widely applied in validating antibody specificity and cross‑reactivity, profiling biopharmaceutical purity and degradation, analyzing post‑translational modifications such as glycosylation and phosphorylation, and identifying host cell protein impurities.
MAGLUMI X8 Fully Automated Chemiluminescence Immunoassay Analyzer
MAGLUMI X8 achieves ultra‑high throughput of 600 tests per hour, equipped with a four‑station high‑speed magnetic separation module, patented pipetting technology to eliminate cross‑contamination, a 42‑item reagent menu, and remote monitoring and diagnostics, enabling trace detection down to 10⁻²¹ mol/L to meet demanding trace analysis requirements; it is primarily used for biopharmaceutical potency quantitation, ADA and NAb immunogenicity testing, biomarker measurement, PK/PD analysis, and batch release testing of monoclonal antibodies and vaccines.
SuPerMax 3000AL Multimode Microplate Reader
SuPerMax 3000AL integrates a grating monochromator covering 190–1000 nm, a dual‑beam optical path, and three detection modes of absorbance, fluorescence, and chemiluminescence, enabling full 96‑well reading in just six seconds while providing onboard incubation from RT+4°C to 65°C and automatic shaking; fully compliant with GMP/GLP and FDA 21 CFR Part 11, it also includes audit trails for complete data traceability, supporting antibody titer determination, HCP and Protein A residue quantitation, cytokine profiling, potency screening, and hybridoma supernatant analysis during early antibody discovery.
Core Testing & Application Services
PharmaAnalytica's Immunoassy Platform enables comprehensive, end-to-end solutions for critical biopharmaceutical testing and R&D needs, covering both routine quality control and cutting-edge research.
Target Validation, Mechanism Study, and Drug Design
Validates target druggability, verifies drug-target interaction specificity, and elucidates molecular mechanisms of action. It screens high-affinity antibodies/ligands, maps epitope binding sites, and investigates downstream signaling pathways—laying the groundwork for rational drug design, lead optimization, and candidate selection.
Impurity and Residue Detection
Detects and quantifies trace impurities critical for drug safety: host cell proteins (HCPs), residual DNA, Protein A leachables, endotoxins, and viral contaminants. It meets ICH, FDA, and pharmacopoeia limits, ensuring product safety, purity, and compliance throughout manufacturing and release.
Purity, Integrity, and Degradation Analysis
Performs qualitative and semi-quantitative assessment of biologic drug purity, structural integrity, and degradation profiles. By detecting full-length molecules, fragmented variants, aggregates, and post-translational modifications (e.g., glycosylation, phosphorylation), the platform evaluates stability under manufacturing, storage, and stress conditions. This ensures batch-to-batch consistency, supports stability studies, and guides formulation optimization—critical for antibody drugs, ADCs, and recombinant proteins.
Potency and Activity Assay
Quantifies binding activity, neutralizing activity, and relative potency of biologic drugs, including monoclonal antibodies, vaccines, and cytokines. It measures target binding affinity, functional efficacy, and lot consistency, providing pivotal data for batch release, stability monitoring, and comparability studies. This directly supports efficacy validation and dosage optimization for therapeutic biologics.
PharmaAnalytica's Immunoassay Platform stands as a comprehensive, compliant, and cost-effective solution that unifies cutting-edge immunoassay technologies with robust instrumentation. It delivers unmatched versatility, spanning early target discovery, lead optimization, preclinical testing, and quality control—eliminating silos and streamlining workflows. The integration of high-sensitivity detection (chemiluminescence/fluorescence), high-throughput automation, and precise molecular interaction analysis ensures data accuracy, reproducibility, and traceability, meeting global pharmacopoeia requirements. The platform's seamless alignment with biopharmaceutical development workflows, makes it an indispensable tool for accelerating drug innovation, ensuring product safety and efficacy, and driving regulatory compliance in the global biopharmaceutical industry.
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Need More Information or Request A Quotation?
Related Links
